Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-09-13
2011-11-22
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S422000, C546S276400, C546S279100, C548S518000
Reexamination Certificate
active
08063078
ABSTRACT:
Certain compounds of formula (I),or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein R1, R2, P, P′, n, p, q, r and s are as defined in the specification, a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.
REFERENCES:
patent: 3424760 (1969-01-01), Welstead et al.
patent: 3424761 (1969-01-01), Lunsford et al.
patent: 4001422 (1977-01-01), Danilewicz et al.
patent: 7220856 (2007-05-01), Dunning et al.
patent: 0401903 (1990-12-01), None
patent: 0347000 (1994-10-01), None
patent: 0790240 (1997-08-01), None
patent: 1392651 (2004-03-01), None
patent: 2226313 (1990-06-01), None
patent: 2000080085 (2000-03-01), None
patent: 20020880073 (2002-03-01), None
patent: 2004527571 (2004-09-01), None
patent: 9209285 (1992-06-01), None
patent: 9219618 (1992-11-01), None
patent: 9900121 (1999-01-01), None
patent: 9900128 (1999-01-01), None
patent: 0050387 (2000-08-01), None
patent: 0055139 (2000-09-01), None
patent: 0128987 (2001-04-01), None
patent: 0208221 (2002-01-01), None
patent: 0216317 (2002-02-01), None
patent: 0216318 (2002-02-01), None
patent: 0216319 (2002-02-01), None
patent: 02090326 (2002-11-01), None
patent: 03022809 (2003-03-01), None
patent: WO 2004/024710 (2004-03-01), None
patent: 2004056394 (2004-07-01), None
patent: 2005103018 (2005-11-01), None
10489277—STN preliminary—02142010.
U.S. Appl. No. 60/451,687.
Vippagunta et al., Advanced Drug Delivery Reviews, vol. 48, p. 3-26.
Pi-Chi Pan, Chung-Ming Sun; Soluble Polymer-Supported Synthesis of Arylpiperazines; Tetrahedron Letters; 1998; 39 No. 511998; 9505-9508; .
Masters, J. J et al; Non-Amidine-Containing 1,2-Dibenzamidobenzene Inhibitors of Human Factor Xa with Potent Anticoagulant and Antithrombotic Activity; Journal of Medicinal Chemistry; 2000; 43 (11); 2087-2092.
Taniguchi, Nobuaki et al; Preparation of heteroyclic moiety-containing benzonitrile derivatives a antiangrogen agents; Database Caplus online; Mar. 26, 2002; 136; 279475; Chemical Abstracts Service; Columbis, Ohio, US.
Hacksell, U et al; 3-Phenylpiperidines. Central dopamine-autoreceptor stimulating activity; Journal of Medicinal Chemistry; 1981; 24; 1475-1482.
Le Bars D et al; Animal models of Nociception; Pharmacological Reviews; 2001; 53; 597-652.
March et al; Advanced Organic Chemistry; 1992; 4; 1216-1218.
March et al; Advanced Organic Chemistry; 1992; 4; 417.
Hassan, J et al; Aryl-aryl bond formation one century after the discovery of the Ullmann reaction.; Chem Rev; 2002; 102; 1359-1469.
Helsley G. C. et.al.; Synthesis and Biological Activity of some 1-substitutes 3-pyrrolidinylureas; Journal of Medicinal Chemistry; 1968; 11 (5); 1034-1037; Am. Chem. Soc.; Washington, US.
Gamage Sa et al; Structure-activity relationships for pyrido-, imidazo-, pyrazolo-, pyrazino-, and pyrrolophenazinecarboxamides as topoisomerase-targeted anticancer agents.; Journal of Medicinal Chemistry; 2002; 45; 740-743.
Smart, D et al; The endogenous lipid anandamide is a full agaonist at the human vanilloid receptor (hVR1).; British Journal of Pharmacology; 2000; 129; 227-230.
March et al; Advanced Organic Chemistry; 1992; 4; 1212.
March et al; Advanced Organic Chemistry; 1992; 4; 378-383.
Berge S M et al; Pharmaceutical Salts; Journal of Pharmaceutical Sciences; 1977; 66, 1; 1-19.
Vorbruggen H.; Advances in Animation of Nitrogen Heterocycles; Advances in Heterocyclic Chemistry; 1990; 49; 117.
Langer M et al; Novel Peptide conjugates for tumor-specific chemotherapy; Journal of Medicinal Chemistry; 2001; 44, 9; 1341-1348.
Graf E et al; Synthesis of 6-Phenyl substituted 2-formylnicotinates.; Synthesis; 1999; 7; 1216-1222.
March et al; Advanced Organic Chemistry; 1992; 4; 419-421.
Szallasi, A., et al.; Vanilloid (Capsaicin) Receptors and Mechanisms; Pharmacological Reviews by the American Society for Pharmacology and Experimental Therapeutics; 1999; 51(2); 159-211.
Freer, R., et al.; Synthesis of Symmetrical and Unsymmetrical Ureas Using Unsymmetrical Diaryl Carbonates; Synthetic Communications; 1996; 26(2); 331-349.
Alonso, D.A., et al.; Lithiated B-Aminoalkyl Sulfones As Mono and Dinucleophiles in the Preparation of Nitrogen Heterocycles: Application to the Synthesis of Capsazepine; Tetrahedron Letters; 1997; 53(13); 4791-4814.
Janusz, J.M., et al.; Vanilloids. 1. Analogs of Capsaicin With Antinociceptive and Antiinflammatory Activity; Journal of Medicinal Chemistry; 1993; 36(18); 2595-2604.
Carr, G E, et al; Sodium Perfluoroalkane Carbgoxylates as Sources of Perfluoroalkyl Groups; Journal of Chem. Soc Perkin Trans 1; 1988; 921-926.
Haga, T, et al; Some New 2-substituted 5-trifluoromethylpyridines; Hetercycles (J for Reviews and Communications in Heter ocyclic Chemistry); 1984; 22 (1); 117-124.
Chizh et al.; The effects of the TRPV1 antagonist Sb-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans; Pain; Oct. 3 2007; 132(1-2); 132-141.
Gunthorpe, M.J. et al.; Characterization of Sb-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor.; Journal of Pharmacology and Experimental Therapeutics; 2007; 321(3); 1183-1192.
Alenmyr L., et al.; TRPV1-mediated itch in seasonal allergic rhinitis.; Allergy: European Journal of Allergy and Clinical Immunology; May 5 2009; 64(5); 807-810.
Sanchez, Joseph P et. al.; Quinolone Antibacterial AGents. Synthesis and Structure-Activity Relationships of a Series of Amino Acid Prodrugs of Racemic and Chiral 7-(3-Amino-1-pyrrolidinyl)quinolones. Highly Soluble Quinolone Prodrugs with inVivo Pseudomonas Activity; Journal of Medicinal Chemistry; 1992; 35; 1764-1773; Am. Chem. Soc.; Washington, US.
Pope, B M; DI-tert-Butyl dicardbonate; Organic Synthesis; 1978; 57; 45; .
Sinha, Birandra K, et al; Synthesis and Antitumor Properties of Bis(Quinaldine) Derivatives; Journal of Medicinal Chemistry; 1977; 20; 1528; Am. Chem. Soc.; Washington, US.
Sato, T et al; A convenient synthetic method of 1, 3-disubstituted isoquinolines using silver trifluoromethanesulfonate as a key reagent; Chemical Letters; 1983; 791-794; The Chemical Society of Japan.
Greene, T W; Protective groups in organic synthesis; Wiley Book; 1981; Wiley.
Rami Harshad Kantilal
Thompson Mervyn
Brink Robert H.
Chu Yong
GlaxoSmithKline LLC
LandOfFree
Urea-compounds active as vanilloid receptor antagonists for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Urea-compounds active as vanilloid receptor antagonists for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Urea-compounds active as vanilloid receptor antagonists for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4283447